TY - JOUR
T1 - Updating the OMERACT filter
T2 - Implications for patient-reported outcomes
AU - Kirwan, John R.
AU - Bartlett, Susan J.
AU - Beaton, Dorcas E.
AU - Boers, Maarten
AU - Bosworth, Ailsa
AU - Brooks, Peter M.
AU - Choy, Ernest
AU - de Wit, Maarten
AU - Guillemin, Francis
AU - Hewlett, Sarah
AU - Kvien, Tore K.
AU - Landewé, Robert B.
AU - Leong, Amye L.
AU - Lyddiatt, Anne
AU - March, Lyn
AU - May, James
AU - Montie, Pamela Lesley
AU - Nikaï, Enkeleida
AU - Richards, Pam
AU - Voshaar, Marieke M.J.H.
AU - Smeets, Wilma
AU - Strand, Vibeke
AU - Tugwell, Peter
AU - Gossec, Laure
PY - 2014/5
Y1 - 2014/5
N2 - Objective: At a previous Outcome Measures in Rheumatology (OMERACT) meeting, participants reflected on the underlying methods of patient-reported outcome (PRO) instrument development. The participants requested proposals for more explicit instrument development protocols that would contribute to an enhanced version of the " Truth" statement in the OMERACT Filter, a widely used guide for outcome validation. In the present OMERACT session, we explored to what extent thesenew Filter 2.0 proposals were practicable, feasible, and already being applied. Methods: Following overview presentations, discussion groups critically reviewed the extent to which case studies of current OMERACT Working Groups complied with or negated the proposed PRO development framework, whether these observations had a more general application, and what issues remained to be resolved. Results: Several aspects of PRO development were recognized as particularly important, and the need to directly involve patients at every stage of an iterative PRO development program was endorsed. This included recognition that patients contribute as partners in the research and not merely as subjects. Correct communication of concepts with the words used in questionnaires was central to their performance as measuring instruments, and ensuring this understanding crossed cultural and linguistic boundaries was important in international studies or comparisons. Conclusion: Participants recognized, endorsed, and were generally already putting into practice the principles of PRO development presented in the plenary session. Further work is needed on some existing instruments and on establishing widespread good practice for working in close collaboration with patients.
AB - Objective: At a previous Outcome Measures in Rheumatology (OMERACT) meeting, participants reflected on the underlying methods of patient-reported outcome (PRO) instrument development. The participants requested proposals for more explicit instrument development protocols that would contribute to an enhanced version of the " Truth" statement in the OMERACT Filter, a widely used guide for outcome validation. In the present OMERACT session, we explored to what extent thesenew Filter 2.0 proposals were practicable, feasible, and already being applied. Methods: Following overview presentations, discussion groups critically reviewed the extent to which case studies of current OMERACT Working Groups complied with or negated the proposed PRO development framework, whether these observations had a more general application, and what issues remained to be resolved. Results: Several aspects of PRO development were recognized as particularly important, and the need to directly involve patients at every stage of an iterative PRO development program was endorsed. This included recognition that patients contribute as partners in the research and not merely as subjects. Correct communication of concepts with the words used in questionnaires was central to their performance as measuring instruments, and ensuring this understanding crossed cultural and linguistic boundaries was important in international studies or comparisons. Conclusion: Participants recognized, endorsed, and were generally already putting into practice the principles of PRO development presented in the plenary session. Further work is needed on some existing instruments and on establishing widespread good practice for working in close collaboration with patients.
KW - Outcome and process assessment
KW - Patient-reported outcomes
KW - Randomized controlled trials
UR - http://www.scopus.com/inward/record.url?scp=84899744683&partnerID=8YFLogxK
U2 - 10.3899/jrheum.131312
DO - 10.3899/jrheum.131312
M3 - Article
AN - SCOPUS:84899744683
SN - 0315-162X
VL - 41
SP - 1011
EP - 1015
JO - The Journal of Rheumatology
JF - The Journal of Rheumatology
IS - 5
ER -